Cargando…

Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers

OBJECTIVES: Humoral immunity wanes over time after two-dose BNT162b2 vaccination. Emerging variants of concern, such as the B.1.617.2 (delta) variant, are increasingly responsible for breakthrough infections owing to their higher transmissibility and partial immune escape. Longitudinal data on neutr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benning, Louise, Morath, Christian, Bartenschlager, Marie, Reineke, Marvin, Töllner, Maximilian, Nusshag, Christian, Kälble, Florian, Reichel, Paula, Schaier, Matthias, Klein, Katrin, Schnitzler, Paul, Zeier, Martin, Süsal, Caner, Bartenschlager, Ralf, Speer, Claudius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810439/ https://www.ncbi.nlm.nih.gov/pubmed/35124261 http://dx.doi.org/10.1016/j.cmi.2022.01.011

Ejemplares similares

Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients
por: Benning, Louise, et al.
Publicado: (2022)

Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2
por: Speer, Claudius, et al.
Publicado: (2021)

Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients
por: Benning, Louise, et al.
Publicado: (2022)

Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy
por: Töllner, Maximilian, et al.
Publicado: (2022)

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients
por: Benning, Louise, et al.
Publicado: (2022)

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
por: Benning, Louise, et al.
Publicado: (2021)

Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
por: Speer, Claudius, et al.
Publicado: (2021)

BA.1/BA.5 Immunogenicity, Reactogenicity, and Disease Activity after COVID-19 Vaccination in Patients with ANCA-Associated Vasculitis: A Prospective Observational Cohort Study
por: Speer, Claudius, et al.
Publicado: (2023)

Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid
por: Benning, Louise, et al.
Publicado: (2022)

Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks
por: Speer, Claudius, et al.
Publicado: (2021)

Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption
por: Kälble, Florian, et al.
Publicado: (2021)

Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis
por: Speer, Claudius, et al.
Publicado: (2020)

Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: A comparative cohort study
por: Speer, Claudius, et al.
Publicado: (2021)

Donor-Derived Cell-Free DNA (dd-cfDNA) in Kidney Transplant Recipients With Indication Biopsy—Results of a Prospective Single-Center Trial
por: Benning, Louise, et al.
Publicado: (2023)

Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients
por: Morath, Christian, et al.
Publicado: (2022)

Membranous nephropathy followed by anti-glomerular basement disease: A case report and review of clinical presentation and treatment
por: Speer, Claudius, et al.
Publicado: (2018)

Clinical Relevance of HLA Antibody Monitoring after Kidney Transplantation
por: Morath, Christian, et al.
Publicado: (2014)

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
por: Wall, Emma C, et al.
Publicado: (2021)

Glomerular filtration barrier dysfunction in a self-limiting, RNA virus-induced glomerulopathy resembles findings in idiopathic nephrotic syndromes
por: Nusshag, Christian, et al.
Publicado: (2020)

Liver-Support Therapies in Critical Illness—A Comparative Analysis of Procedural Characteristics and Safety
por: Göth, Daniel, et al.
Publicado: (2023)

Genetic emergence of B.1.617.2 in COVID-19
por: Kirola, L.
Publicado: (2021)

ABO-Incompatible Kidney Transplantation
por: Morath, Christian, et al.
Publicado: (2017)

Analysis of the Delta Variant B.1.617.2 COVID-19
por: Shiehzadegan, Shayan, et al.
Publicado: (2021)

Clinical Relevance of HLA Antibodies in Kidney Transplantation: Recent Data from the Heidelberg Transplant Center and the Collaborative Transplant Study
por: Süsal, Caner, et al.
Publicado: (2017)

Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco
por: Melloul, Marouane, et al.
Publicado: (2021)

Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022)

Vaccine effectiveness against the B.1.617.2 in the intensive care unit
por: Koc, Ibrahim, et al.
Publicado: (2023)

Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study
por: Nusshag, Christian, et al.
Publicado: (2019)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages
por: Jahrsdörfer, Bernd, et al.
Publicado: (2022)

The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant
por: Cai, Changjing, et al.
Publicado: (2021)

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
por: Lopez Bernal, Jamie, et al.
Publicado: (2021)

Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers
por: Kemp, Steven A., et al.
Publicado: (2022)

Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience
por: Nusshag, Christian, et al.
Publicado: (2021)

Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge
por: Adhikari, Emily H., et al.
Publicado: (2022)

Serial intervals in SARS-CoV-2 B.1.617.2 variant cases
por: Pung, Rachael, et al.
Publicado: (2021)

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins
por: Prandi, Ingrid Guarnetti, et al.
Publicado: (2022)

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
por: Mlcochova, Petra, et al.
Publicado: (2021)

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial
por: Morath, Christian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k2ppvgmsl99hfs33sg3qt98q5u